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Abstract: Adrenocortical insufficiency occurs when there is inadequate release of cortisol 
from the adrenal cortex. Disturbances of the hypothalamic–pituitary–adrenal axis are common 
following trauma, surgical stress, and critical illness. While this is often a protective mechanism, 
these responses may become “uncoupled” or maladaptive resulting in an exacerbation of organ 
failure and higher mortality rates. In these clinical settings, the patient presents with a persistent 
systemic inflammation state, a hyperdynamic cardiovascular response, and vasopressor depen-
dent shock. As such, the occurrence of adrenal insufficiency in the setting of critical illness is 
most appropriately termed critical illness-related corticosteroid insufficiency. In these settings, 
recent data suggests that these patients may benefit from a short course of low-dose steroid 
replacement therapy. Cosyntropin, a synthetic derivative of adrenocorticotropic hormone, is 
being used with increased frequency in the evaluation and diagnosis of adrenocortical insuf-
ficiency in this patient population. A random cortisol level is checked before a 250-µg injection 
of cosyntropin and then 30–60 minutes later. The cortisol levels and response to cosyntropin may 
be interpreted to identify an insufficient adrenal response.  Of note, the setting of critical illness 
can greatly affect the cosyntropin test sensitivity on identifying adrenal insufficiency. Changes 
in the stress response during critical illness combined with the resuscitation and management 
of these patients greatly disturbs serum protein levels, especially those of albumin and transcor-
tin. Common intensive care unit (ICU) diagnoses such as sepsis and malnutrition can increase 
baseline levels and blunt the cortisol response to cosyntropin stimulation, respectively. As well, 
numerous pharmacological agents routinely used in the ICU have been shown to interfere with 
cortisol levels and cosyntropin responsiveness. While steroids have a place in the ICU, specific 
dosing and length of administration remain inconsistent
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Adrenocortical insufficiency
Adrenocortical insufficiency occurs when there is inadequate release of cortisol from 
the adrenal cortex. The incidence rate of adrenal insufficiency is approximately five 
cases per million people per year with a prevalence of 35 to 60 cases per million in 
Western countries.1,2 Primary adrenal insufficiency is due to an impairment of the 
adrenal glands, while secondary adrenal insufficiency is caused by impairment of the 
pituitary gland, tertiary insufficiency is due to hypothalamic dysfunction. Intrinsic 
adrenal disease arises from three general mechanisms: congenital adrenal hypoplasia, 
defective steroid synthesis, and adrenal destruction (from autoimmune causes, 
infection, adrenal replacement by metastatic tumor, and adrenal hemorrhage as in 
Waterhouse–Friderichsen syndrome) (Table 1). Clinical Pharmacology: Advances and Applications 2010:2 78
Hamilton and Cotton Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Secondary adrenal insufficiency appears mainly as a 
manifestation of discontinuation of steroid therapy. Less 
common causes of secondary adrenal insufficiency include 
pan-hypopituitarism secondary to neoplastic or infiltrative 
replacement, granulomatous disease, and pituitary hemor-
rhage or infarction (Sheehan’s syndrome). The classical Addi-
son’s disease describes patients with tuberculous destruction 
of the adrenal gland manifested as anemic patients with skin 
hyperpigmentation, weakness, electrolyte disturbances, nau-
sea, vomiting, and hypotension. Irritability, depression, and 
salt-craving are other chronic symptoms. While tuberculosis 
remains the most common cause of primary adrenal insuf-
ficiency in developing nations, autoimmune destruction of 
the adrenal glands has become the leading cause of primary 
adrenal insufficiency in Western countries.3
Acute adrenal insufficiency (Addisonian crisis) refers to 
the acute onset of hypotension, hyponatremia, hypoglycemia, 
hyperkalemia, and shock. Hyponatremia is present in approx-
imately 90% of cases and hyperkalemia in 65%. Additionally 
the blood urea nitrogen concentration is usually elevated. 
Hyperkalemia occurs because of aldosterone deficiency, and 
therefore is more common in patients with primary adrenal 
insufficiency than in patients with secondary adrenal insuf-
ficiency. Hypercalcemia occurs in 6% of all cases, and may 
be particularly marked in patients with coexisting thyrotoxi-
cosis. However, free thyroxine concentrations are usually low 
or normal, and thyroid-stimulating hormone (TSH) values 
are frequently moderately elevated.4,5 Patients taking supra-
physiologic dosages of exogenous steroids for more than 
three weeks are at risk for secondary adrenal insufficiency 
as return of a competent hypothalamic-pituitary-adrenal axis 
may take up to eight to twelve months.6
Disturbances of the hypothalamic–pituitary–adrenal axis 
(HPA) axis are common following trauma, surgical stress, 
and critical illness.6–11 This is often an adaptive and protective 
mechanism, the integrity of which, determines in part the 
response of the patient to injury and stress. However, the 
response to these challenges may become “uncoupled” or 
maladaptive, resulting in a systemic inflammatory response 
state that precipitates the development of multisystem organ 
failure and leads to higher mortality rates. Although “classic” 
adrenal insufficiency is uncommon in these settings, occult 
or relative adrenal insufficiency has been noted in up to 
60% of severely ill or injured patients.12–14 In these clinical 
settings, the patient presents with a persistent systemic 
inflammation state, a hyperdynamic cardiovascular response, 
and vasopressor dependent shock. As such, the occurrence of 
adrenal insufficiency in the setting of critical illness is most 
appropriately termed critical illness-related corticosteroid 
insufficiency (CIRCI).28,44
Treatment of adrenal insufficiency centers around cortisol 
replacement. Over 90% of circulating cortisol is bound to 
corticosteroid-binding globulin with less than 10% in the free, 
biologically active form.15,16 Nonstressed daily production of 
cortisol in adults is approximately 15 to 25 mg/day and the 
maximal stressed daily production of cortisol is approxi-
mately 200 to 350 mg/day. Based on this data, a daily dose 
of hydrocortisone (or equivalent) of 25 to 200 mg/day should 
be considered a low dose, 200 to 350 mg/day should be con-
sidered as a physiological stress dose, 351 to 1,000 mg/day 
is a supraphysiologic dose, and more than 1,000 mg/day is 
considered as being high dose corticosteroid therapy.17 In the 
setting of relative or occult adrenal insufficiency, recent data 
suggests that these patients may benefit from a short course 
of low-dose steroid replacement therapy. This is usually 
delivered as 200 mg of hydrocortisone in a divided dose.
Cosyntropin: pharmacology  
and pharmacokinetics
Cosyntropin is a synthetic derivative of adrenocorticotropic 
hormone (ACTH) that is used in the evaluation and diagno-
sis of patients with adrenocortical insufficiency. ACTH is a 
naturally occurring peptide hormone that is secreted by the 
anterior pituitary to act on the cells of the adrenal cortex to 
Table 1 Causes of adrenal insufficiency
Primary Autoimmune adrenalitis
Metastatic carcinoma
infection (Hiv, Tb, Fungal)
Hemorrhage/infarction (disseminated intravascular 
coagulation, meningococcemia, anticoagulation,  
heparin-induced thrombocytopenia)
Sepsis
Drugs (ketoconazole, etomidate, mitotane,  
metyrapone)
Hypothermia
Genetic (adrenoleukodystrophy, autoimmune  
polyglandular disease)
iatrogenic (post-adrenalectomy)
Secondary Chronic steroid use
Pituitary or metastatic tumor
Pituitary surgery or radiation
empty-sella syndrome
Craniopharyngioma
infection (Hiv, sarcoidosis, histiocytosis)
Head trauma
  Post-partum pituitary necrosis (Sheehan’s syndrome)
Abbreviations: HIV, human immunodeficiency virus; Tb, tuberculosis.Clinical Pharmacology: Advances and Applications 2010:2 79
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increase secretion of glucocorticoids, mineralocorticoids, 
and sex steroids. Cosyntropin is an open chain polypeptide 
containing the first 24 of the 39 amino acids of natural 
ACTH. It stimulates adrenal activity to the same extent of 
natural ACTH.18 The biologic activity of ACTH resides in 
the N-terminal portion of the molecule and the 1–20 amino 
acid residue is the minimal sequence retaining full activity. 
Progressive shortening of the chain beyond 20 amino acid 
residues results in partial or complete loss of activity. For 
example, the decrement from 20 to 19 results in a 70% loss 
of potency. Cosyntropin is sometimes referred to outside of 
the United States as tetracosactide.
The pharmacologic profile of cosyntropin is similar to 
that of purified natural ACTH. A single dose of 0.25 mg of 
cosyntropin will stimulate the adrenal cortex maximally and 
to the same extent as 25 units of natural ACTH. The half-life 
of cortisol is in the range of 70 to 120 minutes. However, the 
half-life for cosyntropin is only 15 minutes. Administration is 
by intravenous or intramuscular injection and a rise in cortisol 
should generally be seen around 30 minutes after administra-
tion. Plasma cortisol levels usually peak about 45 to 60 minutes 
after injection and a normal response is an approximate dou-
bling of the basal plasma cortisol value. A number of other 
agents may interfere with cosyntropin function and subsequent 
response. These include metyrapone, etomidate, ketoconazole, 
megesterol, and mitotate to name a few. In addition, agents such 
as rifampin and phenytoin may increase cortisol metabolism.
Cosyntropin has also been used to eliminate fluctuations 
in aldosterone levels during adrenal venous sampling for 
aldosteronoma localization. Blood is obtained from the right 
and left adrenal veins, the inferior vena cava, or the peripheral 
veins. The key diagnostic feature in the case of an adenoma 
is unilateral elevation of aldosterone, with suppression of 
contralateral aldosterone. Levels drawn from the inferior 
vena cava or peripheral samples should be higher than from 
the contralateral suppressed gland.19
Side effects of cosyntropin include nausea, anxiety, sweat-
ing, dizziness, itchy skin, redness and or swelling at injection 
site, palpitations, and facial flushing.18 Rarely seen side effects 
include fainting, headache, blurred vision, severe swelling, 
severe dizziness, trouble breathing, or an irregular heartbeat. 
A rare hypersensitivity reaction usually associated with a pre-
existing allergic disease or prior ACTH allergy is possible. 
Bradycardia, tachycardia, hypertension, peripheral edema 
have all been reported after administration of cosyntropin. 
Additionally, cosyntropin may accentuate the electrolyte loss 
associated with diuretic therapy. Cosyntropin is pregnancy 
Category C; meaning it is not known if cosyntropin can cause 
fetal harm or affect reproduction capacity. Administration to 
a pregnant woman should only be if clearly needed. Caution 
should also be exercised when cosyntropin is administered 
to a woman who is breastfeeding. The extra-adrenal effects, 
which natural ACTH and cosyntropin have in common, 
include increased melanotropic activity, increased growth 
hormone secretion, and lipogenesis. These are considered to 
be without physiological or clinical significance.
Cosyntropin and the diagnosis  
of adrenal insufficiency
In the setting of primary and secondary adrenal insufficiency, 
random cortisol levels alone are usually not adequate in 
providing a diagnosis because of the wide fluctuations due to 
the pulsatile nature and diurnal variation of secretion. Cortisol 
levels typically are highest early in the morning and at their low-
est near midnight. The cortisol response to cosyntropin displays 
great variability among healthy persons. Several factors affect 
the response including, stress level, body composition, serum 
corticosteroid-binding globulin level, and individual differences 
in the HPA axis. The cosyntropin test works well in patients 
with primary adrenal insufficiency, but the lower sensitivity in 
patients with secondary adrenal insufficiency necessitates the 
use of tests involving stimulation of the hypothalamus if the 
Table 2 American College of Critical Care Medicine’s task force 
guidelines for diagnosis and management of adrenal insufficiency 
in critical illness
Diagnosis of adrenal insufficiency
1.   Adrenal insufficiency is best diagnosed by a change in cortisol  
(after 250 µg cosyntropin) of 9 µg/dL or a random total  
cortisol of 10 µg/dL.
2.   Free cortisol measurements cannot be recommended for routine use 
at this time.
3.   ACTH stimulation testing should not be used to identify those patients 
with septic shock or ArDS who should receive glucocorticoid therapy.
Treatment of adrenal insufficiency
1.   Hydrocortisone should be considered in patients with septic shock 
who have responded poorly to fluid resuscitation and vasopressor 
agents.
2.   Moderate-dose glucocorticoid therapy should be considered in 
patients with early severe ArDS (PaO2/FiO2 of 200) and before  
day 14 in patients with unresolving ArDS.
3.   Patients with septic shock should be treated for seven days before 
tapering, while patients with early ArDS should be treated for 14 days 
before tapering.
Notes: Adapted from: Marik Pe, Pastores SM, Annane D, et al. recommendations 
for the diagnosis and management of corticosteroid insufficiency in critically ill adult 
patients: consensus statements from an international task force by the American Col-
lege of Critical Care Medicine. Crit Care Med. 2008;36(6):1937–1949.
Abbreviations: ACTH, adrenocorticotropic hormone; ARDS, acute respiratory 
distress syndrome.Clinical Pharmacology: Advances and Applications 2010:2 80
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pretest probability is sufficiently high. The operating character-
istics of the 250 µg and 1 µg cosyntropin tests are similar.20
The low-dose ACTH stimulation test (1 µg) has been 
shown to be more sensitive and specific than the high-dose 
test (250 µg), however; the high-dose test is preferred since the 
low-dose test has not been validated.20,21 The test has a reported 
specificity of 95%, with sensitivities of 97%, 57%, and 61% 
for primary adrenal insufficiency (250 µg cosyntropin test), 
secondary adrenal insufficiency (250 µg cosyntropin test), 
and secondary adrenal insufficiency (1 µg cosyntropin test), 
respectively. Therefore the cosyntropin stimulation test is 
helpful for ruling in secondary AI, but not for ruling it out.20 In 
unstressed subjects, adrenal insufficiency is confirmed when 
the baseline cortisol is less than 3 µg/dL or the 250 µg ACTH-
stimulated cortisol is less than18–20 µg/dL.3,20,22 Alternatively 
suspected AI can be diagnosed with a post-cosyntropin level 
of at least 20 µg/dL for primary AI and at least 25–30 µg/dL 
for secondary AI.
The diagnosis and treatment of adrenal insufficiency in 
critical illness has been the subject of controversy for over 
30 years. In 1977, Sibbald and colleagues reported that almost 
20% of patients in septic shock have subnormal responses 
to ACTH administration.23 Since that time, however, the 
diagnosis (and even the existence) of CIRCI has been highly 
debated. Specifically, tumor necrosis factor (TNF) alfa and 
interleukin-1 (IL-1) have been implicated as inflammatory 
mediators in the reversible dysfunction of the HPA axis 
during critical illness. TNF-α likely impairs corticotropin-
releasing hormone stimulated ACTH release, and a number 
of clinical studies have reported inappropriately low ACTH 
levels in patients with severe sepsis.24,25 The incidence of 
CIRCI varies widely from 10% to 71% depending of the 
definition used.26 However, making a clinical diagnosis is 
difficult in critically ill patients because systemic vascular 
resistance, cardiac output, and pulmonary capillary wedge 
pressure can be low, normal, or even high.27
While multiple tests have been developed to diagnose 
CIRCI, the most commonly used test is the ACTH stimulation 
test. In this setting, random cortisol levels are checked before a 
250 µg injection of cosyntropin and then 30–60 minutes later. 
The cortisol levels and response to cosyntropin may be inter-
preted to identify an insufficient adrenal response. Currently, 
either a random cortisol of less than 10 to 15 µg/dL or changes 
in cortisol of less than 9 µg/dL are the best tests for the diag-
nosis of adrenal insufficiency. Both values have an acceptably 
high specificity but low sensitivity.28 Several authors have 
demonstrated that nonsurvivors generally have higher baseline 
cortisol levels and a lower cortisol response to ACTH.26,29 
However, free serum cortisol levels can be normal in critically 
ill patients who have low total serum cortisol; most likely as a 
result of a reduction in binding proteins during times of injury, 
stress and critical illness.30 Hamrahian and colleagues inves-
tigated total and free cortisol as well as cosyntropin stimula-
tion responses in healthy volunteers and patients with sepsis. 
The authors found that while total cortisol levels were often 
consistent with adrenal insufficiency, free cortisol levels (not 
impacted by hypoproteinemia) demonstrated that these same 
patients had normal adrenal function. In patients with severe 
hypoproteinemia, adrenal insufficiency may be best defined 
by a baseline serum free cortisol concentration less than 
2.0 µg/dL or ACTH-stimulated free cortisol concentrations 
less than 3.1 µg/dL.
In the 1990’s, several papers indicated a potential benefit 
of a brief course of corticosteroid therapy in critically ill 
patients (specifically those with vasopressor-dependent septic 
shock) who failed an ACTH stimulation test.8,31,32 However, 
in 2008, the results of the multicenter, multinational COR-
TICUS trial demonstrated that hydrocortisone cannot be 
recommended as general adjuvant therapy for vasopressor 
responsive septic shock.33 As well, the authors concluded 
that corticotropin testing could not be recommended to 
determine which patients should receive hydrocortisone 
therapy. In that trial, hydrocortisone did not improve survival 
or reverse shock, in patients with septic shock, either overall 
or in patients who did not respond to cosyntropin. It was 
noted however that in responders, the shock was reversed 
much faster.33
Of note is that the setting of critical illness can in, and of 
itself, greatly affect the cosyntropin test sensitivity in identi-
fying adrenal insufficiency. The stress of critical illness and 
injury can greatly increase cortisol production while increas-
ing glucocorticoid resistance.28 The changes in the stress 
response during critical illness combined with the resuscita-
tion and management of these patients greatly disturbs serum 
protein levels, especially those of albumin and transcortin. 
With lower levels of these binding proteins, baseline cortisol 
and post-stimulation levels are generally lower than in similar 
states where albumin levels are normal. Complicating this, 
frequent intensive care unit (ICU) diagnoses such as sepsis 
and malnutrition can increase baseline levels and blunt the 
cortisol response to cosyntropin stimulation, respectively.
Further complicating the diagnosis of CIRCI in the ICU 
setting are the numerous commonly used agents that have 
been shown to interfere (in varying degrees) with cortisol 
levels and cosyntropin responsiveness. Several pharma-
cologic agents frequently used in the severely injured and Clinical Pharmacology: Advances and Applications 2010:2 81
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critically ill populations have been shown to impair adrenal 
function and steroidogenesis.34–36 Propofol impairs adrenal 
steroidogenesis, while agents such as midazolam, morphine, 
and fentanyl have been shown to blunt the HPA axis, thereby 
interfering with corticosteroid metabolism. Etomidate is an 
imidazole derivative frequently used as an induction agent 
for rapid sequence intubation. In critically ill and injured 
patients, etomidate has gained increasing popularity for its 
rapid onset of action, cardiovascular stability, and limited 
respiratory depression.13 However, it is well established that 
adrenal suppression (via inhibition of 11-b hydroxylase), 
has brought the use of etomidate into question.13,37,38 In fact, 
among the major risk factors (coagulopathy, mechanical 
ventilation, hemorrhagic shock, vasopressor use, and septic 
shock) evaluated by Cotton and colleagues, etomidate use 
was the only modifiable risk factor identified.13
A single dose of etomidate has been demonstrated to 
inhibit cortisol production for up to 48 hours.39 Exposure to 
etomidate is a risk factor for the development of CIRCI in 
critically injured patients, and alternative drugs should be 
used when possible.13 In a reanalysis of a double blind clinical 
trial of 299 patients with septic shock randomized to receive 
placebo or corticosteroids, 77 (26%) patients received etomi-
date.40,41 Of these, 94% did not respond well to cosyntropin 
stimulation and the blockade of steroidogenesis lasted around 
72 hours. More importantly, mortality was different between 
etomidate treated patients randomized to placebo (76%) and 
those randomized to corticosteroids (55%). This statistically 
significant absolute risk reduction of 21% translates into a 
number needed to treat of five patients.
Clearly steroids have a place in the ICU. However, their 
dosing and length of administration remain inconsistent. 
The use of extended course, stress-dose corticosteroids has 
been evaluated in ten randomized controlled clinical trials 
in critically ill patients with sepsis and acute respiratory 
distress syndrome (ARDS). This dosing strategy has been 
reported to be associated with a reduction in mortality, more 
rapid weaning of vasopressor agents, decreased ICU length 
of stay, and an increase in ventilator-free days in ARDS.28 
Randomized controlled trials evaluating the outcomes of 
high-dose, short course corticosteroid treatment in ARDS 
and sepsis and have been unable to show improved outcomes, 
and there was a higher incidence of complications in the 
patients who received high-dose corticosteroids.42,43 Treat-
ment with moderate-dose corticosteroids is recommended 
in patients with septic shock who have responded poorly 
to volume resuscitation and vasopressor agents. In patients 
with early severe ARDS and unresolving ARDS, treatment 
with moderate dose glucocorticoids should be considered 
before day 14.
Although previous studies have suggested that the treat-
ment of patients with septic shock should be based on the 
results of a cosyntropin stimulation test, the limitations of 
this test in diagnosing adrenal insufficiency in the setting of 
critical illness, combined with the benefit of corticosteroids 
in both responders and nonresponders suggest that this test 
should not be used to select patients likely to derive benefit 
from corticosteroids.44 In a recent critical appraisal of how 
to approach this patients population when relative or occult 
adrenal insufficiency is suspected, Marik recommends initiat-
ing treatment with stress-doses of corticosteroids in patients 
with vasopressor-dependent septic shock within 12 hours of 
presentation. He also recommends doing so without stimula-
tion testing but rather based on clinical suspicion or random 
free cortisol levels.
Conclusion
Cosyntropin is a synthetic derivative of ACTH that is used 
in the evaluation and diagnosis of patients with adrenocorti-
cal insufficiency. Cosyntropin stimulation testing remains 
the cornerstone of diagnosing both primary and secondary 
adrenal insufficiency. While both the low-dose (1 µg) and 
high-dose versions (250 µg) have been shown to diagnose 
adrenal insufficiency, the 1 µg dose has been shown to be 
more sensitive and specific. However, its poor specificity in 
secondary adrenal insufficiency limits its use in definitively 
ruling out this diagnosis. In the critically ill patient population 
presenting with CIRCI, based on currently available data, 
stimulation testing of adrenal function should not be routinely 
performed. Steroid therapy should be started presumptively 
in hemodynamically unstable patients while those who are 
stable may await random cortisol level results.
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